- Chief Development Officer Dave Flory to present corporate overview and review Kuria's development plans for diseases of the cornea and retina
Kuria Therapeutics, a pharmaceutical company developing a platform of novel Nrf2 activators for ophthalmic disease, has been selected for participation at the Southwest Venture Forum meeting in Dallas, hosted by the Caruth Institute for Entrepreneurship at Southern Methodist University. Kuria's Chief Development Officer, Dave Flory, will present on Kuria's development programs to develop novel Nrf2 activators to Power Sight in blinding diseases of the retina and cornea.
Kuria's live presentation will occur at 7 am CST on November 16 at the Park City Club in Dallas.
About Kuria Therapeutics, Inc.:
Kuria Therapeutics, Inc. is a US-based pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic disease. We are a team of seasoned life science executives and entrepreneurs with decades of experience in building biotechnology companies, running complex multi-national development programs, managing alliances with partners, and building relationships with clinicians, investors, vendors, and patient groups. For more information, visit www.kuriatx.com.
Contacts Investor Relations and Media Kuria Therapeutics: Corporate Communication info@kuriatx.com